He is vice president, US Regulatory Affairs, for Novo Nordisk (NYSE:NVO) where he provides strategic leadership to a team of more than 50 regulatory staff and scientists in the development of new medicines and advises the global executive team on matters related to drug development programs, FDA liaison strategies, managing FDA-related compliance issues, and monitoring emerging US regulatory trends and opportunities. Importantly for IHL, Clark and his team have secured FDA approvals for 12 significant new drugs for Novo Nordisk since he began with he company in 2012. Prior to joining Nova Nordisk, Clark was vice president of Worldwide Regulatory Strategy and US Regulatory Affairs at Pfizer, leading a team of up to 150 regional regulatory professionals supporting the drug development continuum.